Diagnostic use of contrast medium and the kidney: A challenge or a ghost?

Abstract

The global growing number of contrast-enhanced procedures highlights the risk of contrast media–induced renal damage. This review is an effort to define contrast-induced nephropathy and its pathogenesis, weigh its principal risk factors, give some clarifications about kidney function evaluation tools, acquire some clinical relevance prognostic concerns, and bring into focus preventive measures, with special regard to cancer patients. Our final purpose is focused on the request of diagnostic safety in high-risk patients, which may be achieved without unfair differences in this subgroup, too. A second reading of the scientific evidence may offer a chance to tear down the kidney damage ghost, replacing it with the consciousness of a still existing challenge that engages more than one specialty.

Keywords

Contrast medium chronic kidney disease cancer patients acute kidney injury

Get full access to this article

View all access options for this article.

References

Katzberg

Haller

. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl 2006; 100: S3–S7.

Launay-Vacher

. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30: 548–556.

Cosmai

Porta

Gallieni

et al . Onco-nephrology: a decalogue. Nephrol Dial Transplant 2016; 31: 515–519.

Solomon

. Contrast media: are there differences in nephrotoxicity among contrast media? Biomed Res Int 2014; 2014: 934–947.

Older

. Contrast-induced renal failure: a radiological problem and radiological diagnosis. Radiology 1979; 131: 553–554.

Contrast media and the kidney. Brit Med J 1971;2: 4–5.

Scherberich

Fischer

Rautschka

et al . Nephrotoxicity of high and low osmolar contrast media: case control studies following digital subtraction angiography in potential risk patients. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd 1989; 128: 91–94.

Swanson

Thrall

Shetty

. Evaluation of intravascular low-osmolality contrast agents. Clin Pharm 1986; 5: 877–891.

Barrett

Carlisle

. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171–178.

10.

Weisbord

SD1

Mor

Resnick

et al . Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol 2008; 3: 1274–1281.

11.

Sendensky

Persson

Liu

et al . Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta. Am J Physiol Renal Physiol 2012; 303: F1592–F1598.

12.

Jost

Lengsfeld

Lenhard

et al . Viscosity of iodinated contrast agents during renal excretion. Eur J Radiol 2001; 80: 373–377.

13.

Heyman

Rosen

Khamaisi

et al . Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol 2010; 45: 188–195.

14.

Hooste

Doom

De Waele

et al . Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis. Intensive Care Med 2011; 37: 1921–1931.

15.

Newhouse

Kho

Rao

et al . Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191: 376–382.

16.

KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150.

17.

Sendur

Aksoy

Yaman

et al . Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity. J BUON 2013; 18: 274–280.

18.

Cicin

Erdogan

Gulsen

et al . Incidence of contrast-induced nephropathy in hospitalised patients with cancer. Eur Radiol 2014; 24: 184–190.

19.

Janowitz

Williams

Marshall

et al . New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol 2017; 35: 2798–2805.

20.

Zeng

McMahon

Brunelli

et al . Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol 2014; 9: 12–20.

21.

Nash

Hafeez

Hou

. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930–936.

22.

Karanikola

Karaonalis

Galyfos

et al . Endovascular management of atherosclerotic renal artery stenosis: post-cardiovascular outcomes in renal atherosclerotic lesions era winner or false alarm? Vasc Specialist Int 2017; 33: 1–15.

23.

Grossman

Ali

Aronow

et al . Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Interv Cardiol 2017; 30: 274–280.

24.

McCullough

Wolyn

Rocher

et al . Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368–375.

25.

Aubry

Brillet

Catella

et al . Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures. BMC Nephrol 2016; 17: 167.

26.

Mehran

Aymong

Nikolsky

et al . A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393–1399.

27.

Sadeghi

Stone

Grines

et al . Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769–2775.

28.

Gruberg

Mehran

Dangas

et al . Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001; 52: 409–416.

29.

Scolari

Ravani

. Atheroembolic renal disease. Lancet 2010; 8: 1650–1650.

30.

Freeman

O’Donnell

et al . Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068–1073.

31.

Gurm

Dixon

Smith

et al . Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2011; 58: 907–914.

32.

Cigarroa

Lange

Williams

et al . Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86: 649–652.

33.

Marenzi

Assanelli

Campodonico

et al . Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009; 150: 170–177.

34.

Nyman

Almén

Jacobsson

et al . Are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections? Eur Radiol 2012; 22: 1366–1371.

35.

McDonald

Leake

McDonald

et al . Acute kidney injury after intravenous versus intra-arterial contrast material administration in a paired cohort. Invest Radiol 2016; 51: 804–809.

36.

Turedi

Erdem

Karaca

et al . The high risk of contrast-induced nephropathy in patients with suspected pulmonary embolism despite three different prophylaxis: a randomized controlled trial. Acad Emerg Med 2016; 23: 1136–1145.

37.

Lakhal

Ehrmann

Chaari

et al . Acute Kidney Injury Network definition of contrast-induced nephropathy in the critically ill: incidence and outcome. J Crit Care 2011; 26: 593–599.

38.

Lee

Cho

Lee

et al . Contrast-induced nephropathy in patients undergoing intravenous contrast-enhanced computed tomography in Korea: a multi-institutional study in 101487 patients. Korean J Radiol 2014; 15: 456–463.

39.

Tepel

van der Giet

Schwarzfeld

et al . Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–184.

40.

Barrett

Katzberg

Thomsen

et al . Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006; 41: 815–821.

41.

Thomsen

Morcos

Erley

et al . The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 2008; 43: 170–178.

42.

Kuhn

Chen

Sahani

et al . The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 2008; 191: 151–157.

43.

Nijssen

Rennenberg

Nelemans

et al . Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389: 1312–1322.

44.

Weisbord

Mor

Resnick

et al . Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med 2008; 168: 1325–1332.

45.

Mitchell

Jones

Tumlin

et al . Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol 2010; 5: 4–9.

46.

Kim

Cha

Lee

et al . Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report. Am J Kidney Dis 2010; 55: 1018–1025.

47.

Balemans

Reichert

Van Schelven

et al . Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology 2012; 263: 706–713.

48.

Brenner

Cooper

de Zeeuw

et al . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

49.

Subramaniam

Wilson

Turban

et al . Contrast-induced nephropathy: comparative effectiveness of preventive measures. Rockville, MD: Agency for Healthcare Research and Quality, 2016.

50.

ESUR guidelines on contrast media (version 9.0), 2014. http://www.esur.org/guidelines/History%20of%20the%20Contrast%20Media%20Guidelines.pdf

51.

ACR Committee on Drugs and Contrast Media. ACR manual on contrast media (version 10.3), 2017. https://www.acr.org/Clinical-Resources/Contrast-Manual

52.

Cruz

Perazzella

Bellomo

et al . Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 2006; 48: 361–371.

53.

Weinstein

Heyman

Brezis

. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413–415.

54.

Stevens

McCullough

Tobin

et al . A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. J Am Coll Cardiol 1999; 33: 403–411.

55.

Marenzi

Ferrari

Marana

et al . Prevention of contrast nephropathy by furosemide with matched hydration the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. J Am Coll Cardiol Intv 2012; 5: 90–97.

56.

Zhou

Song

et al . Effect of angiotensin-converting enzyme inhibitors in contrast-induced nephropathy: a meta-analysis. Nephron 2016; 133: 1–14.

57.

Peng

Lin

et al . Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis. J Cardiovasc Pharmacol 2015; 65: 262–268.

58.

McDonald

Katzberg

McDonald

et al . Is the presence of a solitary kidney an independent risk factor for acute kidney injury after contrast-enhanced CT? Radiology 2016; 278: 74–81.

59.

Fotino

. The solitary kidney: a model of chronic hyperfiltration in humans. Am J Kidney Dis 1989; 13: 88–98.

60.

Hsieh

Chiu

How

et al . Contrast medium exposure during computed tomography and risk of development of end-stage renal disease in patients with chronic kidney disease: a nationwide population-based, propensity score-matched, longitudinal follow-up study. Medicine 2016; 95: e3388.

61.

Hong

Ahn

Lee

et al . Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer 2016; 24: 1011–1017.

62.

Shaw

Bell

et al . Effect of IV contrast medium on renal function in oncologic patients undergoing CT in ICU. AJR Am J Roentgenol 2010; 195: 414–422.

63.

Fortalesa Melo

Chojniak

Costa Silva

et al . Use of cystatin C and serum creatinine for the diagnosis of contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography at an oncology centre. PLoS ONE 2015; 10: e0122877.

64.

Cheruvu

Henning

Mulligan

et al . Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations. J Comput Assist Tomogr 2007; 31: 493–498.

65.

Park

Lee

. Renal assessment using CKD-EPI equation is useful as an early predictor of contrast- induced nephropathy in elderly patients with cancer. J Geriatr Oncol 2017; 8: 44–49.

66.

Bellomo

Ronco

Kellum

et al . Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–R212.

67.

Metha

Kellum

Shah

et al . Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.

68.

Kidney Disease Improving Global Outcomes (KDIGO) and Acute Kidney Injury Work Group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl 2012; 2(1): 1–138.

69.

Waikar

Bonventre

. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2009; 20: 672–679.